1. Home
  2. ACOR

ACOR

Acorda Therapeutics Inc.

Logo Acorda Therapeutics Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-18-2024 1:52pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. The company's Net product revenue is derived from the sales of Ampyra and Inbrija.

Founded: 1995 Country:
United States
United States
Employees: N/A City: PEARL RIVER
Market Cap: 821.0K IPO Year: 2006
Target Price: N/A AVG Volume (30 days): 125.7K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -203.57 EPS Growth: N/A
52 Week Low/High: $0.61 - $24.20 Next Earning Date: 05-09-2024
Revenue: $117,633,000 Revenue Growth: -0.79%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Similar to ACOR Stocks: